Download This Paper
Preprints with The Lancet is a collaboration between The Lancet Group of journals and SSRN to facilitate the open sharing of preprints for early engagement, community comment, and collaboration. Preprints available here are not Lancet publications or necessarily under review with a Lancet journal. These preprints are early-stage research papers that have not been peer-reviewed. The usual SSRN checks and a Lancet-specific check for appropriateness and transparency have been applied. The findings should not be used for clinical or public health decision-making or presented without highlighting these facts. For more information, please see the FAQs.
A Novel Signature of 23 Immunity-Related Gene Pairs is Prognostic of Cutaneous Melanoma
45 Pages Posted: 14 Aug 2020
More...Abstract
Background: As clinical behavior of cutaneous melanoma (CM) is unpredictable rendering the prediction of survival time and tumor stage particularly difficult. Thus novel biomarkers and patient-tailored treatments and are needed.
Methods: Construction data from The Cancer Genome Atlas (TCGA)(n = 471), validation data from three microarray datasets: GSE65904 (n = 214), GSE59455 (n = 141), and GSE22153 (n = 79). We used TCGA samples to develop the best prognostic signature. Next we divided patients into high- and low-immune risk group to assess ability of the 23-IRGP signature in all datasets.
Findings: 23-IRGP present precise ability in CM which high-risk groups showed poor prognosis in all datasets. C-index in TCGA training-, testing-, GSE65904-, GSE59455- and GSE22153- dataset was 0.775 (95% CI = 0.748–0.802), 0.636 (95% CI = 0.585–0.687), 0.650 (95% CI = 0.609–0.691), 0.557 (95% CI = 0.508–0.606), and 0.610 (95% CI = 0.537–0.683), respectively. The 23-IRGP signature present higher predict power than IRGs prognostic signature and showed significant predict ability in immune micro-environment and biological analysis as well.
Interpretation: In this study, we established a novel prognostic model which was revealed as a promising prognostic signature in CM. This approach can be applied to discover the signatures in other different kinds of diseases without technical bias from different platforms.
Funding Statement: This study was supported by the General Projects of National Natural Science Foundation of China (No. 81671918).
Declaration of Interests: The authors have declared that no conflicts of interest exist.
Keywords: Immune related gene pairs (IRGPs); CM; immune micro-environment; prognosis
Suggested Citation: Suggested Citation